Search Results

£1 million award to develop gene therapy for rare blood disorder FHL-2

Professor Bobby Gaspar is to receive investment of up to £1million from the UCL Technology Fund (UCLTF) to support development of a gene therapy for familial haemophagocytic lymphohistiocytosis (FHL type 2 or ‘FHL-2’) through to a clinical trial.

UCL Therapeutic Innovation Networks (TINs) Launch Event

The UCL Translational Research Office (TRO) is delighted to announce that the official launch of the UCL Therapeutic Innovation Networks (TINs)

The event will showcase the Therapeutic Innovation Networks for Cell, Gene and Regenerative Medicines; Biologics; Small Molecules; Devices and Diagnostics; Repurposing.